Surgery Partners, Inc.

SGRY Healthcare Medical Care Facilities

Surgery Partners, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.3 billion, up 6.24% from fiscal 2024.

Revenue
+2.75%
EPS
−500.0%
Free cash flow
−60.6%
Total debt
+4.92%

Quarter to June 2026, against a year earlier

23.18 0.02 +0.09%
Market cap
$3.0B
P/E
0.0×
Fwd P/E
−35.3×
Dividend yield
—
F-score
4/9
Altman Z
0.75
Beneish M
−2.52
Dividend safety
4/100

Surgery Partners, Inc. (SGRY) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Surgery Partners, Inc. (SGRY) trades at a EV/EBITDA of 11.2×. Over the past ten years it has ranged from 8.4× (March 2026) to 20.0× (June 2021); the current reading is higher than 36% of that period. That is below the Medical Care Facilities industry median of 11.9× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 9.2× (16.74%)
FY2024 11.1× (22.17%)
FY2023 14.2× 41.38%
FY2022 10.1× (35.31%)
FY2021 15.6× 13.61%
FY2020 13.7× 36.24%
FY2019 10.1× (40.68%)
FY2018 17.0× 38.07%
FY2017 12.3× 39.67%
FY2016 8.8× (14.24%)

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 9.8× 14.46%
Mar 2026 8.5× (7.47%)
Dec 2025 9.2× (12.49%)
Sep 2025 10.5× (6.42%)
42 more quarters

Against its own ten years

Low 8.4× High 20.0×
Ten-year median 12.0×
Current reading's percentile 36

EV/EBITDA against peers

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on SGRY